Search Results
Abstract
Backgrounds: Skin wounds are a kind of refractory disease frequently encountered in clinic, which brings enormous burden to patients. Great efforts to address the dilemma of wound healing have yielded some encouraging results, but they are still unsatisfactory. 5-aminolevulinic acid (ALA)-mediated photodynamic therapy (PDT) has been developed as a promising noninvasive treatment for skin wounds. A systematic review was performed to determine the existing evidence base for the clinical use of ALA-PDT on refractory wounds.
Methods: We conducted a PubMed search for English literature related to the clinical treatment of human skin ulcers by ALA-PDT published from 2012 to 2022, and performed a systematic review.
Results: 25 studies were ultimately selected in the present review and summarized, including six studies of skin cancer, five studies of chronic leg ulcers, three studies of erosive pustular skin diseases, and two studies of erosive oral lichen planus symptoms. A total of 335 patients had approximately 355 ulcers, of which 315 ulcers received photodynamic therapy and 276 improved with ALA-PDT. 20% ALA solution, wavelength between 600 nm and 670 nm, energy density of 120 J/cm2, frequency of once per week and 3 sessions were the most selected therapeutic parameters. Generally, ALA-PDT for wounds was effective with main adverse events of mild to moderate pain, and follow-up was generally conducted within 1 year.
Conclusions: This systematic review summarized the commonly used therapeutic parameters for ALA-PDT in the clinical treatment of skin wounds. After ALA-PDT alone or ALA-PDT combined with curettage, antibacterial and surgical treatment, all wounds healed well, and the adverse reactions were mainly mild to moderate pain, which could be relieved by cooling. ALA-PDT had proven to be a promising wound treatment modality through evidence of safety and efficacy.
Skin grafting provides an effective means of closing chronic wounds. Autografts and allografts are used most often in skin grafting, but Apligraf, a tissue-engineered bilayered human skin equivalent, provides another safe and effective grafting option for treating diabetic, venous, and pressure ulcers. This skin equivalent has an epidermis and dermis similar to human skin, largely due to its derivation from neonatal foreskin. Apligraf is also easily accessible and has shown little immunoreactivity. (J Am Podiatr Med Assoc 92(1): 19-23, 2002)
DermACELL: Human Acellular Dermal Matrix Allograft
A Case Report
Diabetes often causes ulcers on the feet of diabetic patients. A 56-year-old, insulin-dependent, diabetic woman presented to the wound care center with a Wagner grade 3 ulcer of the right heel. She reported a 3-week history of ulceration with moderate drainage and odor and had a history of ulceration and osteomyelitis in the contralateral limb. Rigorous wound care, including hospitalization; surgical incision and drainage; intravenous antibiotic drug therapy; vacuum-assisted therapy; and a new room temperature, sterile, human acellular dermal matrix graft were used to heal the wound, save her limb, and restore her activities of daily living. This case presentation involves alternative treatment of a diabetic foot ulcer with this new acellular dermal matrix, DermACELL.
Reinforcement of the Flexor Tendon Repair Using Human Amniotic Membrane
A Biomechanical Evaluation Using the Modified Kessler Method of Tendon Repair
Background:
Human amniotic membrane is used to prevent peritendinous adhesions after tendon injuries. This study compares the mechanical properties of modified Kessler repairs and modified Kessler repairs strengthened using multiple layers of human amniotic membrane.
Methods:
Twenty flexor digitorum profundus tendons of sheep forelimbs were sutured by the two-strand modified Kessler technique (group A) and by the two-strand modified Kessler repair reinforced with multiple layers of human amniotic membrane (group B). To assess the mechanical performance of the repairs, tendons were subjected to a linear noncyclic load-to-failure test using a material testing machine. Outcome measures included ultimate forces and the mode of failure.
Results:
The mean ± SD value of the failure strength was 34.6 ± 1.64 N for group A and 50.6 ± 5.60 N for group B. The reinforced repair provided a significantly higher ultimate load compared with the nonreinforced group (P < .001). All of the specimens failed due to suture breakage at the repair site.
Conclusions:
The results of this study show that the modified Kessler repair can be reinforced effectively with human amniotic membrane.
Background
We describe a retrospective study that uses the Broström-type surgical procedure with modifications that augment deficient and torn ligaments with acellular human dermal grafts. At the onset of this study, the most prevalent dermal graft available to us was GraftJacket (Wright Medical Technology, Arlington, Tennessee). Greater than 50% of the study participants were grafted with this product, but more recently other equally effective human dermal grafts have been used with no apparent difference.
Methods
Thirty-five lateral ankle stabilization procedures were performed in the past 6 years on 33 patients. Eight patients were considered athletes (mean age, 23 years). The balance of the study group consisted of sedentary patients (mean age, 41 years). The mean patient body mass index (calculated as the weight in kilograms divided by the square of the height in meters) was 31.
Results
All of the patients were satisfied with their results, with no recurrent instability. Two patients in this group went on to have contralateral ankle stabilization in a similar manner owing to their satisfaction. Complications included two soft-tissue infections.
Conclusions
Lateral ankle stabilization using acellular human dermal graft augmentation is a useful tool in the surgical treatment of ankle instability. This procedure offers distinct advantages over traditional methods of ankle repair and can be performed with relatively limited surgical exposure. Ease of operation, consistent results, and limited patient morbidity should allow surgeons to use this procedure independently or adjunctively to improve surgical outcomes.
Normal Genetic Variation of the Human Foot: Part 2
Population Variance, Epigenetic Mechanisms, and Developmental Constraint in Function
Congenital deformities of the foot have been reported to correlate with regulatory epigenetic mechanisms that are also responsible for the timing and sequencing of developmental growth of the lower limb. Developmental variance of normal morphologic features has also been shown to vary between populations despite the retention of human foot characteristics. The molecular evidence for genetically controlled expressions of common evolved physical features is highly suggestive of regulatory control mechanisms that act together with developmental constraints to homogenize the retained functional characteristics of the foot. Genetic variance in morphologic features and functional plasticity when linked to morphometric change during gait may prove influential in clarifying kinematic and kinetic relationships (J Am Podiatr Med Assoc 102(2): 149–156, 2012)
Plantar Verrucae in Patients with Human Immunodeficiency Virus
Clinical Presentation and Treatment Response
Several previous studies have yielded data showing that plantar and other cutaneous verrucae follow a more aggressive course in patients infected with human immunodeficiency virus (HIV) than in uninfected individuals. A pilot study was undertaken to identify trends in a sample population that would support this characterization of plantar verrucae in HIV+ patients and to determine whether there are differences in treatment response between HIV+ and HIV− patients. The results show that the HIV+ patients in the study presented with a significantly greater number and total area of lesions than did the HIV− patients. Furthermore, the HIV+ patients experienced a greater frequency of recurrence of their lesions following treatment with surgical curettage. These findings should provide the foundation for other extensive, multicenter studies to further characterize the treatment response of these lesions in HIV+ patients and to develop effective guidelines for their management. (J Am Podiatr Med Assoc 91(2): 79-84, 2001)
Background:
Radiographic imaging of the foot is commonly performed when medical evaluation is indicated. Angular measurements between bones may be assessed as part of the examination for trauma and foot biomechanics. However, angular relationships between surfaces of the physical bone as they compare with the bone's radiographic image has had limited investigation.
Methods:
For this study, 54 human feet from amputated limbs were imaged in standard radiographic views and skeletonized. Selected angular measurements were taken on each skeletonized talus and calcaneus and were compared with those taken from radiographic images using paired Student t tests and linear regression analysis.
Results:
Transverse plane measurements of the talus were not significantly different (P ≥ .05), associating strongly (r2 = 0.67–0.75; all P < .001). Most transverse and sagittal plane measurements of the calcaneus were not significantly different (P ≥ .05), with transverse plane measurements more strongly associated (r2 = 0.70–0.77; all P < .001) than sagittal plane measurements (r2 = 0.35–0.78; all P < .001).
Conclusions:
Selected angular measurements of the talus and calcaneus taken from radiographic images can be compared quantitatively with the physical bone, demonstrating that angular measurements from radiographic images provide useful information concerning both of these bones. This knowledge can be applied to the understanding of the morphology of the calcaneus and talus as it relates to human foot biomechanics and should also be of use in the interpretation of the human fossil pedal record.
Studies have been conducted to evaluate the efficacy of dehydrated human amnion chorion membrane (dHACM) in treating recalcitrant diabetic foot ulcers. A literature search was performed to review the data collected from the use of dHACM allografts. Two products were explicitly named in these publications, EpiFix and AmnioBand Membrane. Relevant results included the healing rate, number of wounds healed, and number of grafts used. Data had supported the potential of lowering the overall cost to manage a wound despite a relatively higher cost per dressing. However, discrepancy was observed in the rate of healing between several of the studies. Nonetheless, dHACM had demonstrated improvement in healing of recalcitrant diabetic foot ulcers compared to standard of care alone. These results provide grounds for more inclusive research on dHACM in the future.
Micronized Dehydrated Human Amnion/Chorion Membrane Injection in the Treatment of Chronic Achilles Tendinitis
A Large Retrospective Case Series
Background
Human amniotic membrane contains growth factors and cytokines that promote epithelial cell migration and proliferation, stimulate metabolic processes that lead to collagen synthesis, and attract fibroblasts, while also reducing pain and inflammation. Randomized studies have shown effectiveness of micronized dehydrated human amnion/chorion membrane (mdHACM) allograft injection in treatment of plantar fasciitis. We present our experience and short-term outcomes with using mdHACM injection as a treatment for Achilles tendinopathy.
Methods
Retrospective case series of patients with Achilles tendinopathy treated with mdHACM by a single physician. Participants had at least two follow-up visits within 45 days of mdHACM injection. Outcomes examined included change in reported level of pain during the 45-day observation period and treatment-associated adverse events.
Results
Follow-up data were available for 32 mdHACM-treated patients. At treatment initiation, 97% of patients reported severe (66%) or moderate (31%) pain. At the first follow-up visit (mean ± SD of 8.1 ± 2.7 days postinjection), 27 patients (84%) reported improvement in pain levels, although 37% of patients continued to report severe (6%) or moderate (31%) pain. At the second follow-up visit (mean ± SD of 23.1 ± 6.2 days postinjection), no patients reported severe pain and one reported moderate pain. Within 45 days of mdHACM injection, complete symptom resolution was reported by 66% of treated patients (n = 21), with the remaining 34% (n = 11) reporting symptom improvement but not complete resolution. Two patients reported calf or quadricep pain or tightness after injection.
Conclusions
In our experience, mdHACM injection reduced or eliminated pain in all 32 patients with follow-up data.
